Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.53 USD
-0.65 (-7.95%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.68 +0.15 (1.99%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Terns Pharmaceuticals, Inc.'s return on equity, or ROE, is -27.35% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that TERN has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TERN 7.53 -0.65(-7.95%)
Will TERN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Other News for TERN
TERN forms Jack-in-the-box Bullish on September 19
Is TERN set to rally? Expansion Breakout shows up after rocketing 10.54%
Mizuho Securities Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
Roche deal to buy 89bio boosts MASH space
Is TERN compressing before expansion? Bollinger Band Squeeze shows up after rising 1.37%